Early Experience and Effectiveness of Long-Acting Injectable Cabotegravir and Rilpivirine in a South Side Chicago HIV Clinic
We describe referrals and uptake of long-acting injectable cabotegravir/rilpivirine at an academic clinic in Chicago. In a pharmacy-led model, 118 (18%) people with HIV were referred and 78 (12%) initiated long-acting injectable cabotegravir/rilpivirine from 1 January 2021 to 31 May 2023. Implementation, especially for people with HIV who were not virally suppressed, requires further support for patients, providers, and clinic systems.
Authors
- Moira McNulty (ORCID: https://orcid.org/0000-0002-9651-254X)
- Alicia Dawdani
- Geoffroy Liégeon (ORCID: https://orcid.org/0000-0003-1267-4347)
- Eleanor E. Friedman (ORCID: https://orcid.org/0000-0001-5840-9763)
- Paul Djuricich
- Kristen A. Stafford (ORCID: https://orcid.org/0000-0001-5620-6436)
- Sophie Plotkin
- Christopher Kaperak
- J. Schneider (ORCID: https://orcid.org/0009-0003-0553-3447)
- Aniruddha Hazra (ORCID: https://orcid.org/0000-0001-8557-4465)
- Jessica Schmitt (ORCID: https://orcid.org/0000-0001-5125-7808)
- Katerina A. Christopoulos (ORCID: https://orcid.org/0000-0002-8598-2191)
Institutions
- University of California, San Francisco (US)
- University of California System (US)
- University of Illinois Chicago (US)
- University of Chicago (US)
- University of San Francisco (US)
Publication Details
- Journal
- Open Forum Infectious Diseases
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1093/ofid/ofaf094
- Citations
- 3
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 4.19
Funders
- Agence Nationale de Recherches sur le Sida et les Hépatites Virales
- National Institutes of Health